Articles tagged with Cancer Genomics
Researchers found that GATA6 expression is reduced in liver metastases, correlating with poorer clinical outcomes. Losing GATA6 allows cancer cells to change their identity and become more adaptable, leading to metastasis.
Researchers used patient-derived xenograft (PDX) models to study deadly DNA loops in cancer cells. They found significant similarities between human tumor samples and PDX models, including consistent presence of extra copies of oncogenes. These findings suggest that ecDNA-positive tumor cells may drive tumor growth and recurrence.
A comprehensive review of breast cancer risk models in women with a family history found that none are highly accurate at identifying which women will develop the disease. The BOADICEA model showed balanced performance, while others had significant limitations, emphasizing the need for continued improvement.
A comprehensive study of Native American breast cancer tissue reveals molecular differences that may impact treatment efficacy. The study found unique patterns in gene mutations and immune system interactions, highlighting the need for personalized therapies.
Researchers at UT MD Anderson Cancer Center have uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer. Targeting early inflammatory responses by adding TBK1 blockade may be a promising combination strategy to overcome treatment resistance.
Scientists identified distinctive microbial patterns associated with oesophageal squamous cell carcinoma, a mysterious subtype common in South Africa. The study, published in Communications Medicine, suggests a potential low-cost warning signal for early detection using saliva bacteria analysis.
Davis Joseph's groundbreaking discovery identifies three universal cancer types based on protein and RNA malfunction, paving the way for an organ-agnostic treatment. The research also developed a unified apoptosis network flowsheet, comprising approximately 100 pathways, which can be applied to various cancers.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Three young scientists in Israel have been awarded the prestigious Blavatnik Awards for their innovative research in chemistry, cancer biology, and astrophysics. Sergey Semenov, Uri Ben-David, and Paz Beniamini will each receive US$100,000 to advance their projects on complex materials, cancer treatments, and extreme cosmic events.
The Center for Cellular Language Intelligence will decipher the complex communications that govern tumor ecosystems, revealing principles of cellular organization and biological programs influencing cancer initiation and response. Led by Linghua Wang, the center aims to accelerate discovery and deliver new therapeutic targets, predicti...
A specific region of Dicer must be activated to achieve proper cell division and reproduction, a discovery that sheds light on the regulation of this enzyme's critical role in both cancer biology and fertility. This finding opens new avenues for studying how small epigenetic changes contribute to disease.
Researchers have identified a single genetic change that drives the development of myeloid leukaemia in children with Down Syndrome. The study reveals a common vulnerability and treatment target, suggesting potential repurposed treatments. The genetic change, related to the GATA1 gene, is present at all stages of the disease.
The Phase I MYTHIC trial demonstrated a strong synergy between zedoresertib and lunresertib, showing durable regressions and consistent tumor shrinkage in patients with ovarian cancer. The combination achieved an overall disease control rate of 68.5% and a molecular response rate of 47%.
A large DRUP trial reveals that existing targeted cancer therapies can deliver profound and durable benefits, even in heavily pretreated or rare cancers. About one-third of patients responded to treatment or had stable disease for at least four months.
The Cancer Dependency Map Consortium is launching Phase 3 to expand its research beyond cancer vulnerabilities to investigate resistance and surface targets. The consortium aims to develop novel oncology targets and biomarkers for the next generation of cancer therapies.
Researchers identified a CRISPR variant that distinguishes tumor DNA from healthy DNA and selectively cuts the former. This method relies on methyl groups attached to DNA, which are altered in cancer cells.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
Researchers have developed a new single-cell technology called CIPHER-seq that captures the timing of cytokine activity with greater accuracy. This allows for a clearer view of immune cell behavior and strengthens the foundation for understanding cancer, inflammation, and treatment resistance.
A framework has been developed to identify candidate pathogenic variants hidden among uncertain significance variants detected in comprehensive genomic profiling. The framework was tested using BRCA1 and BRCA2 genes, leading to the classification of a previously unknown variant as pathogenic.
Researchers find that rare stromal cells are responsible for maintaining immune cell organization in healthy lymph nodes. However, in aggressive lymphomas, this process breaks down due to a self-reinforcing inflammatory cycle, leading to tissue collapse and poorer outcomes.
A new tool, metapipeline-DNA, automates and standardizes genome sequencing analysis, reducing the complexity of large and complicated data. The open-access resource, developed by Sanford Burnham Prebys and the University of California Los Angeles, aims to improve collaboration and reproducibility across research labs.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Researchers explored using CDK4/6 inhibitors to treat PDAC by targeting RB1, which is often inactivated by oncogenic KRAS. This approach showed promise in inducing cellular senescence, but further combination therapy is needed for therapeutic benefit.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
Researchers analyzed tumour samples from almost 500 domestic cats across five countries, identifying specific driver genes that lead to cancer development. The study found similarities between cat and human cancers, including a common driver gene associated with worse prognosis in humans.
A study analyzing tumours from almost 500 pet cats identified genetic changes that could help treat breast cancer in humans and animals. Similarities were found between feline mammary cancers and human breast cancers, suggesting potential avenues for therapy.
The journal explores the convergence of computational biology, artificial intelligence, and healthcare innovation, with a focus on precision medicine and enhanced patient care. Submissions are accepted from researchers, clinicians, and technologists on topics such as AI in medicine, computational genomics, and drug discovery.
Researchers have identified three unique subtypes of mismatch repair deficient high-grade gliomas, providing a clearer understanding of their development and behavior. The findings are helping guide more precise therapies and offer hope for a potential vaccine to target cancer cells earlier.
A recent study published in PNAS reveals a novel non-coding RNA molecule, CUL1-IPA, that regulates key cellular functions and supports the structural integrity of the nucleolus. The discovery suggests this molecule may influence patient survival in certain blood cancers.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Researchers found that cancer's powerful genetic on switches, called super-enhancers, drive intense gene activity, causing DNA breaks and stress. This can lead to accumulation of mutations over time, fueling cancer's evolution.
The study reveals that low levels of CTDNEP1 drive early and deadly pancreatic tumors, highlighting its role as a tumor suppressor. Tumors with low CTDNEP1 expression showed stronger metabolic activity and immune evasion.
A new study by CNIO has identified two genes in the complement system that increase the risk of pancreatic ductal adenocarcinoma. These genes, FCN1 and PLAT, may serve as biomarkers for screening high-risk populations.
Researchers from The University of Osaka discovered that loss of heterochromatin can trigger genetic changes leading to chromosomal rearrangements and diseases like cancer. Accumulation of R-loops at pericentromeric repeats was found to be a key mechanism in this process.
The partnership enables Fox Chase to implement clinical testing utilizing Arima's 3D-genomics technology for multiple tumor types, guiding diagnosis and treatment. This collaboration accelerates innovation through strategic partnerships integrating basic science, clinical research, and patient care.
A clinical trial by UC San Diego School of Medicine found that personalizing cancer treatments using molecular testing improves treatment success. The study used advanced genomic sequencing to identify unique tumor DNA profiles and developed personalized treatment plans, resulting in better treatment results for patients.
Children's Hospital of Philadelphia researchers have developed a method to help cancer immunotherapies reach 'invisible' tumors. HLA-Shuttle is an engineered protein complex that restores antigen presentation in immunologically 'cold' neuroblastoma cells, identifying previously unknown targets across 30 genes linked to neuroblastoma.
Researchers developed RNACOREX, a new open-source software tool that identifies gene regulation networks in cancer. The tool analyzes thousands of molecules simultaneously to detect key interactions, providing an interpretable molecular map that improves understanding of tumors.
The MUTE-Seq method detects rare cancer mutations at exceptionally low frequencies, enriching circulating tumor DNA and improving detection accuracy. It increases variant allele frequencies by tens of times, enabling detection of mutations present at 0.005% or lower.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
A study compares five DNA foundation language models across 57 diverse datasets to identify their strengths and weaknesses in predicting gene expression, identifying genomic components, and detecting harmful mutations. The findings highlight the importance of selecting appropriate models based on specific genomic tasks.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Researchers have discovered a new class of BRCA1 mutations that can be targeted by HSP90 inhibitors, potentially improving treatment outcomes for patients with breast cancer. The study found that these mutations are more resistant to PARP inhibitor treatment but can be overcome with low-dose HSP90 inhibition.
The Ontario Hereditary Cancer Research Network has created a comprehensive provincial database to support research on cancers passed down through genetics. Ontarians at risk of hereditary cancers can now register for access to clinical trials, advocacy groups, and other resources.
Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
Researchers identified a new subtype of T-cells that do not respond to current treatments and could impact clinical care. A genetic marker, ZBTB16, was found to be switched on in these cells, which can be used to identify them.
A new genetic risk score combines rare and common gene variants with non-coding genome information to predict arrhythmia risk. This comprehensive framework can be applied to other genetically influenced diseases like cancer and Parkinson's Disease.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
A University of Delaware student's unexpected rise as a researcher led to critical new insights into human papillomavirus (HPV) and its role in cancer. The study found that specific mutations in HPV proteins may increase cancer risk, paving the way for improved approaches to diagnosing and treating HPV-related cancers.
Up to 17 million people in the US, approximately 5%, carry genetic mutations associated with cancer risk. The study highlights the importance of routine cancer screenings and suggests expanding genetic testing beyond high-risk groups.
Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.
The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.
The Variant Workbench enables researchers to explore genetic data in a single, integrated workspace, linking genomic information with clinical conditions. By reducing data complexity, the tool facilitates scientific discovery and accelerates pace of research.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.